Animal Health M&A Deals 2026: Global Acquisitions from Jan to Sep 2026

January–September 2026: Deal Values, Enterprise Values, Strategic Synergies and Transaction Status

Reporting period: 1st of January –30th of September 2026
Industry coverage: Animal pharmaceuticals, vaccines, diagnostics, genomics, animal nutrition, veterinary distribution, veterinary practice groups, companion-animal healthcare and selected adjacent pet-care and agricultural transactions

Most Comprehensive M & A Report for AH Industry

The first nine months of 2026 saw consolidation across the animal-health value chain. Strategic buyers pursued differentiated pharmaceutical portfolios, genetics and diagnostic technologies, while private-equity-backed platforms expanded through acquisitions of veterinary hospitals, companion-animal businesses and specialised nutrition companies. Other transactions brought together distribution, digital healthcare and physical veterinary services.

Five strategic themes define the period:

1. Portfolio reshaping: The proposed divestment of dsm-firmenich’s Animal Nutrition & Health business and the proposed Covetrus–MWI combination represent significant structural transactions.

2. Companion-animal healthcare expansion: Chewy’s acquisition of Modern Animal, Tractor Supply’s acquisition of VIP Petcare and the merger of Bond Vet and Small Door illustrate the convergence of veterinary care, pharmacy, digital engagement and retail.

3. Diagnostics and precision technology: Zoetis’ proposed acquisition of Neogen’s animal-genomics business, its VitalRADS transaction and Merck Animal Health’s agreement with TARGAN reflect growing interest in data-led animal healthcare and production technology.

4. Private-equity-backed Platform building: Charterhouse’s acquisition of Animalcare Group and Zenex Animal Health’s acquisitions of VievePharm and SAVAVET illustrate the continuing role of financial sponsors in consolidating fragmented markets.

5. Cross-border Capability Acquisition: Alivira’s agreement to acquire Italy’s BioForLife and the Ceva–Mitsui Japanese joint venture strengthen international market access and product portfolios.

Deal values remain undisclosed for many private-company transactions. Where an enterprise value was not published, this report does not manufacture one from the purchase price, revenue estimates or the value of associated real estate.

Master Transactions Register

Brief Details on Major Strategic Transactions

dsm-firmenich Animal Nutrition & Health — CVC Capital Partners

Announcement: 9 February 2026
Transaction value: Approximately €2.2 billion enterprise value, including an earn-out of up to €500 million
Status: Announced; expected to close at the end of 2026

dsm-firmenich agreed to sell its Animal Nutrition & Health business to CVC Capital Partners. The transaction is part of a broader portfolio strategy designed to concentrate dsm-firmenich on its nutrition, health and beauty activities while placing the animal-nutrition assets under a dedicated owner.

The planned separation encompasses two businesses: a Solutions Company, focused on performance solutions, premixes and precision services; and an Essential Products Company, focused on vitamins, carotenoids and aroma ingredients. dsm-firmenich is expected to retain a 20% equity interest in each business, with CVC holding 80%.

Strategic synergies

• Dedicated ownership and capital allocation for animal-nutrition products.

• Greater focus on premixes, feed performance, precision nutrition and customer-specific solutions.

• Potential operational and commercial improvements under a specialist private-equity owner.

• Continuity through a long-term vitamin supply arrangement with dsm-firmenich.

Deal-value interpretation: The €2.2bn headline is enterprise value, not the amount of cash received by dsm-firmenich at closing. The earn-out is contingent and should be reported separately.

Source: dsm-firmenich transaction announcement

Covetrus — MWI Animal Health

Announcement: 18 February 2026
Transaction value: US$3.5 billion enterprise value for MWI Animal Health
Status: Definitive agreement announced; completion subject to conditions

The proposed transaction would combine Covetrus’ veterinary distribution and technology capabilities with MWI Animal Health, currently part of Cencora.

The announced consideration structure included US$1.25bn in cash, US$800m in preferred equity and US$1.45bn in common equity in the combined company for Cencora. Cencora was expected to retain a 34.3% non-controlling common-equity interest.

Strategic synergies

• Greater scale in veterinary pharmaceutical and medical-supply distribution.

• Potential integration of product fulfilment, veterinary-practice technology and customer support.

• Broader service offerings for companion-animal practices and livestock customers.

• Opportunities to improve procurement economics and distribution efficiency.

Risks: Integration complexity, supplier concentration, customer retention and competition review. The enterprise value should not be confused with the cash component of consideration.

Source: Cencora / Covetrus announcement

Chewy — Modern Animal

Announcement: 8 April 2026; completion on 21 May 2026
Purchase price: US$399.8m estimated purchase price; US$378.0m net cash paid after US$21.8m acquired cash
Status: Completed

Chewy acquired Modern Animal, a technology-enabled veterinary platform with 29 owned clinics, 24/7 virtual care and a membership-based service model. The transaction expanded Chewy Vet Care’s network from 18 to 47 locations.

Modern Animal was expected to contribute more than US$125m in annualised run-rate revenue. Chewy also reported that mature Modern Animal clinics generated revenue per location more than twice the industry average and EBITDA margins above 20%.

Strategic synergies

• Integration of in-person veterinary services with Chewy’s online commerce and pharmacy platform.

• Increased cross-category purchasing and prescription adoption.

• Greater engagement and retention among high-value pet-parent customers.

• Reuse of Modern Animal’s operating technology across Chewy Vet Care.

• A larger network for clinic expansion and virtual-care integration.

Chewy estimated that ecosystem synergies could lift net sales per active customer for the veterinary network by approximately 15–20%. This is management’s expectation, not a realised result.

Enterprise value: No separate enterprise value was established in the sources reviewed. The reported US$399.8m purchase price should not be relabelled as enterprise value.

Source: Chewy’s official acquisition announcement

Charterhouse Capital Partners — Animalcare Group

Announcement: 16 April 2026; scheme effective 30 July; completion announced 31 July
Equity value: Approximately £235.2m
Status: Completed and delisted from AIM

Charterhouse acquired the entire issued and to-be-issued share capital of Animalcare Group at 336 pence per share. Animalcare develops and commercialises animal-health products for companion animals, equine and production animals. Its portfolio includes approximately 150 brands, with core franchises in dental, equine and pain products and a strong presence across Europe and Asia-Pacific.

Strategic synergies

• Long-term investment in product development and pipeline innovation.

• International expansion of established brands.

• A platform for additional acquisitions in a fragmented animal-health market.

• Operational improvements and strengthened commercial execution.

Enterprise value: The approximately £235.2m figure is the announced equity value. A separate enterprise value should be reported only after verifying net debt and other relevant adjustments.

Sources: Charterhouse completion announcement · Scheme-effective announcement

Elanco — AHV International

Completion: 30 April 2026
Consideration: US$76m paid at closing, plus US$100m in guaranteed payments and up to US$140m in contingent consideration
Maximum disclosed consideration: US$316m
Status: Completed

AHV develops farm-animal health solutions intended to improve productivity and animal welfare while reducing reliance on antibiotics. The acquisition adds a specialised technology and commercial portfolio to Elanco’s cattle and dairy-health business.

Strategic synergies

• Greater reach in dairy-herd health and transition-cow management.

• Cross-selling through Elanco’s international commercial network.

• Complementary product development and technical services.

• Broader support for productivity, welfare and responsible antibiotic use.

The maximum potential consideration is not the amount paid at closing. The contingent component depends on the contractual conditions and milestones.

Source: Elanco investor relations

Zoetis — Neogen animal-genomics business

Announcement: 2 March 2026
Value: US$160m, subject to customary adjustments
Status: Announced; original guidance targeted the second half of 2026

Zoetis agreed to acquire Neogen’s animal-genomics business, strengthening its precision animal-health offering through genomic testing, data and livestock selection capabilities.

Strategic synergies

• Integration of genomic information with animal-health and productivity decisions.

• Wider reach for genetic testing through Zoetis’ global commercial network.

• Potential for more predictive breeding and herd-management decisions.

• Complementarity between diagnostic information and intervention strategies.

Enterprise value: Not separately disclosed in the sources reviewed. The US$160m figure is the announced transaction value.

Source: Neogen investor relations

Merck Animal Health — TARGAN

Announcement: 11 June 2026
Value: Undisclosed
Status: Definitive agreement announced; original expectation was Q3 2026

TARGAN develops high-speed poultry-production technology, including systems for sex identification in hatcheries. Merck Animal Health had been an investor in TARGAN since 2017.

Strategic synergies

• Expansion from pharmaceuticals and vaccines into precision poultry equipment.

• Combination of animal-health expertise with automated production technology.

• Potential improvements in hatchery workflow and operational consistency.

• Opportunities to use production data to complement disease prevention and flock management.

Enterprise value: Not disclosed. The Q3 target date is not itself evidence of completed closing.

Source: Merck Animal Health

Zoetis — VitalRADS

Announcement: 14 July 2026
Value: Undisclosed
Status: Acquisition agreement announced; original target was Q3 2026

VitalRADS provides veterinary teleradiology, mobile ultrasound, outpatient imaging, cloud image storage and workflow technology.

Strategic synergies

• Adds specialist image interpretation to Zoetis’ diagnostics portfolio.

• Strengthens a connected reference-laboratory and imaging-services model.

• Supports integrated diagnostic workflows for veterinary clinics.

• Creates opportunities for technology-assisted reporting and quality assurance, subject to clinical oversight.

Enterprise value: Not disclosed. The reviewed announcement did not establish a confirmed closing by 30 September.

Source: Zoetis investor relations

Tractor Supply — VIP Petcare / PetVet

Announcement and acquisition: 28 May 2026
Value: Undisclosed
Status: Acquired

Tractor Supply acquired the veterinary-services business VIP Petcare, operating as VIP Petcare and PetVet, from PetIQ. The business operates community veterinary clinics through retail partners, including Tractor Supply locations, and serves more than one million pets annually.

Strategic synergies

• Integration of veterinary services with Tractor Supply’s rural retail footprint.

• Connection to Allivet’s digital pharmacy capabilities.

• More convenient preventive care in rural and exurban markets.

• Higher customer engagement through the Neighbor’s Club loyalty programme.

• Potential growth in telehealth, pharmacy and repeat preventive-care visits.

This is a veterinary-services acquisition, not a pharmaceutical-company acquisition. Financial terms were not disclosed, so neither purchase price nor enterprise value can be stated reliably.

Source: Tractor Supply official release

BiomEdit — Folium Science technology and pipeline assets

Announcement: 25 August 2026
Value: Undisclosed
Status: Asset acquisition announced

BiomEdit acquired Folium Science’s technology platform and pipeline assets, including BiomElix One, a poultry feed additive approved in Brazil. The transaction also brings CRISPR-based precision microbiome technology into BiomEdit’s capabilities.

Strategic synergies

• Adds an approved commercial asset to a technology-led pipeline.

• Expands the potential for microbiome-based solutions in poultry and animal nutrition.

• Combines precision microbiome technology with existing biologics capabilities.

• Creates options for developing differentiated products targeting livestock performance and health.

Enterprise value: Not applicable as a separately disclosed whole-company enterprise value; the transaction concerns technology and pipeline assets. The purchase price was not disclosed.

Source: BiomEdit’s announcement

Companion-Animal Veterinary Services and Clinics’ Consolidation

Bond Vet — Small Door Veterinary

Announcement: 9 July 2026
Value: Undisclosed
Status: Merger finalised

Bond Vet and Small Door combined to create a veterinary network of more than 55 clinics serving over 500,000 pets across Northeast, Mid-Atlantic and Midwest markets. The companies continue to operate under their existing brands.

Strategic synergies

• Greater geographic scale and broader access to veterinary services.

• Shared operational resources and potential purchasing efficiencies.

• Combination of Small Door’s membership-based care and telemedicine capabilities with Bond Vet’s clinic network.

• Greater ability to recruit, retain and support veterinary teams.

• A platform for future clinic expansion.

The merger’s financial terms were not disclosed. No defensible enterprise value is available from the reviewed public announcement.

Source: Bond Vet and Small Door merger announcement

GoodVets — WellHaven Pet Health

Announcement: 24 September 2026
Value: Undisclosed
Status: Announced before the reporting cut-off; integration and rebranding were expected to follow

GoodVets acquired WellHaven Pet Health, a network of more than 40 veterinary hospitals across seven US states. The acquisition expands GoodVets’ reported network from approximately 75 to 116 hospitals.

Strategic synergies

• Broader geographic coverage, including the Pacific Northwest and Midwest.

• Greater scale in recruiting, training and veterinary operations.

• Potentially more efficient procurement, technology and administrative systems.

• Opportunity to transition hospitals to the GoodVets brand over time.

Enterprise value: Undisclosed. The announcement does not provide a reliable basis for estimating purchase price or enterprise value.

Source: Martis Capital announcement

VetPartners España — MediVet Iberia

2026 regulatory status: Spanish competition authority authorisation on 1 July 2026
Value: Undisclosed
Status: Competition approval obtained; operational completion should be confirmed separately

VetPartners España received first-phase authorisation from Spain’s Comisión Nacional de los Mercados y la Competencia to acquire exclusive control of MediVet Iberia.

Strategic synergies

• Expansion of VetPartners’ Spanish veterinary-practice network.

• Greater operational scale and regional coverage.

• Potential shared procurement, clinical protocols and administrative support.

• Broader opportunities for professional development and specialist referrals.

The competition decision establishes regulatory approval, not necessarily the exact legal closing date. The purchase price and enterprise value were not disclosed in the reviewed authority record.

Source: CNMC case C/1688/26

Four Corners Property Trust — Mission Pet Health Properties

Announcement: 29 May 2026
Value: Up to US$268m
Status: Property acquisition agreement announced; closing should be verified from subsequent filings

Four Corners Property Trust agreed to acquire up to 102 veterinary properties leased to Mission Pet Health. Mission Pet Health was expected to remain the long-term tenant under triple-net leases.

The portfolio had approximately ten years of lease term remaining, with average annual rent escalations exceeding 2%. The transaction was priced from initial cash rent of approximately US$17.33m.

Strategic rationale

This is principally a real-estate investment transaction. It offers Four Corners recurring rental income and diversification into veterinary properties. For Mission Pet Health, a sale-and-leaseback structure can monetise property assets and free capital for veterinary operations and clinic expansion.

Source: Four Corners Property Trust

Animal Pharmaceuticals, Nutrition and Cross-Border Platform Deals

Zenex Animal Health — VievePharm

Announcement: 27 February 2026
Value: Undisclosed
Status: Majority-stake acquisition announced

Zenex Animal Health, backed by Multiples Alternate Asset Management, announced a majority investment in Netherlands-based VievePharm, a specialist in natural animal nutrition and phytogenic formulations.

Strategic synergies

• Entry into a specialised European animal-nutrition platform.

• Additional capabilities in phytogenic formulations and natural feed solutions.

• Broader reach across livestock, equine and companion-animal markets.

• Potential cross-selling through Zenex’s established commercial infrastructure.

No reliable purchase price or enterprise value was disclosed in the reviewed material.

Alivira / Viyash Scientific — BioForLife Italia

Announcement: 8 June 2026
Value: Approximately ₹188 crore; public descriptions also refer to approximately €15m upfront plus deferred consideration
Status: Binding agreement signed; expected closing in Q2 FY2027

Alivira Animal Health, a wholly owned subsidiary of Viyash Scientific, agreed to acquire 100% of BioForLife Italia, a Milan-based companion-animal healthcare company.

BioForLife develops, commercialises and distributes companion-animal products, including nutritional supplements, veterinary medicines, rapid diagnostic tests, dermatology and ophthalmology products. Its commercial organisation reaches more than 80% of veterinary clinics in Italy, according to the acquirer.

Strategic synergies

• Entry into one of Europe’s largest companion-animal healthcare markets.

• Access to an established Italian veterinary commercial network.

• Launch of Alivira pipeline products in Italy.

• Potential expansion of BioForLife products into other Alivira markets.

• Stronger European companion-animal generics presence.

Enterprise value: Not separately disclosed. The announced cash consideration should not automatically be labelled enterprise value.

Source: Alivira announcement

Ceva Santé Animale — Aquilón

Announcement: June 2026
Value: Undisclosed
Status: Acquisition announced; closing details should be verified from the full release

Ceva announced the acquisition of Aquilón, a company associated with swine intestinal health and a European commercial vaccine for swine dysentery linked to Brachyspira hyodysenteriae.

Strategic synergies

• Strengthens Ceva’s swine-health offering.

• Adds specialised intestinal-health technology and vaccine capabilities.

• Expands prevention-focused options for pig producers.

• Provides potential for wider commercial reach and technical support.

The strategic value is in the specialised product and technical capability; no reliable purchase price or enterprise value was disclosed.

Boehringer Ingelheim Animal Health — Evax AG

Announcement: 11 August 2026
Value: Undisclosed
Status: Acquisition announced as completed

Evax is a Swiss biotechnology company working on therapeutic vaccines for horses, including research into allergic skin diseases.

Strategic synergies

• Adds differentiated equine biotechnology to Boehringer Ingelheim’s pipeline.

• Provides a platform for further therapeutic-vaccine development.

• Enables potential access to established development, manufacturing and commercial infrastructure.

• Expands innovation options in conditions that can be difficult to manage through conventional symptomatic treatment.

The commercial value remains dependent on development progress, regulatory outcomes and market adoption.

Ceva Santé Animale and Mitsui — Ceva Bussan Animal Health

Announcement: 8 May 2026
Structure: Joint venture and strategic equity collaboration
Value: Undisclosed
Status: Joint venture announced

Ceva and Mitsui created Ceva Bussan Animal Health by combining Bussan Animal Health with Ceva Japan. Mitsui transferred 60% of its shareholding in Bussan Animal Health to Ceva and made an additional equity investment in Ceva.

Strategic synergies

• Combines Bussan’s longstanding Japanese market presence and veterinary technical-sales organisation with Ceva’s global animal-health portfolio.

• Broadens access to livestock and companion-animal products.

• Supports the introduction of international products into Japan.

• Creates potential to commercialise Japanese-developed products and intellectual property internationally.

• Strengthens collaboration across animal health and animal nutrition.

Source: Mitsui’s official announcement

Pet Nutrition and Wellness Transactions

The Farmer’s Dog — Woof

Announcement: September 2026; completion on 18 September
Value: Undisclosed
Status: Completed

The Farmer’s Dog acquired Woof, a pet-products company known for functional enrichment and wellness products, including its refillable Pupsicle system.

Woof is to continue operating independently under its existing brand and team while gaining access to The Farmer’s Dog’s resources.

Strategic synergies

• Expansion from fresh dog food into enrichment and wellness.

• Potential bundling of nutrition and daily-care products.

• Cross-selling opportunities through customer relationships and digital channels.

• Greater resources for product development and distribution.

Enterprise value: Not disclosed. The purchase price cannot be inferred reliably from brand growth or category estimates.

Source: The Farmer’s Dog acquisition announcement

SALIC — Olam Agri: an adjacent transaction with relevance to the animal-protein value chain

Completion: 27 April 2026
Value: Approximately US$1.88bn for a 44.58% stake; implied 100% equity valuation of approximately US$4.00bn
Status: First tranche completed; SALIC’s stake rose to 80.01%

Saudi Agricultural and Livestock Investment Company (SALIC), a subsidiary of Saudi Arabia’s Public Investment Fund, completed the purchase of an additional 44.58% stake in Olam Agri from Olam Group. Following the transaction, SALIC held 80.01% and Olam Group retained 19.99%. A second tranche was expected within three years, after which Olam Agri would become wholly owned by SALIC.

Strategic relevance to animal health

Olam Agri is not an animal-health company. Its significance lies in the wider food, feed and agricultural supply chain. Grain origination, processing, trading and global agricultural infrastructure can influence feed availability, livestock production economics and food-system resilience.

Potential strategic synergies

• Greater control over a global agriculture and food supply-chain platform.

• Stronger access to agricultural commodities and logistics across multiple markets.

• Support for Saudi food-security and agricultural-investment objectives.

• Indirect relevance to feed availability and livestock-production economics.

Classification: Adjacent agribusiness M&A, not a direct animal-health acquisition. The US$1.88bn figure is the price for the acquired stake, not the enterprise value of an animal-health company.

Sources: Olam Group · SALIC

Zenex Animal Health — SAVAVET / SAVA Healthcare

Transaction announcement: Reported on 1 October 2026
Value: Undisclosed

Zenex acquired the companion-animal business operating under the SAVAVET brand from SAVA Healthcare. The business was reported to have approximately 70 brands spanning parasiticides, antibiotics, cardiac care, pain management, dermatology and wellness, with approximately 165 stockists and relationships with more than 6,000 veterinarians.

Strategic synergies

• Immediate scale in India’s companion-animal medicines market.

• Broader portfolio and established veterinarian relationships.

• Opportunities to integrate SAVAVET’s brands with Zenex’s product development and distribution capabilities.

• Greater diversification across livestock, poultry, companion animals and herbal healthcare.

SAVA retains its farm-animal business and is expected to continue contract manufacturing agreed veterinary products. The divestment allows it to focus more strongly on human-health formulations, R&D, contract manufacturing and international business.

Status: Public reporting states the acquisition was completed, but the completion announcement was published on 1 October.

Source: Express Pharma report

Industry implications

Veterinary services are becoming integrated healthcare platforms

Chewy–Modern Animal, Tractor Supply–VIP Petcare and Bond Vet–Small Door demonstrate how veterinary care is increasingly connected to digital pharmacy, retail, memberships and customer-engagement platforms. The competitive question is no longer simply how many clinics a company owns, but whether it can integrate clinical quality, convenience, retention, prescription fulfilment and operational efficiency.

Diagnostics and technology are becoming strategic assets

Zoetis’ transactions involving genomics and teleradiology, Merck’s TARGAN agreement and BiomEdit’s acquisition of Folium assets illustrate growing interest in technologies that generate actionable data or improve production processes. These deals also carry development and integration risks: strategic relevance does not guarantee rapid financial returns.

Private equity is supporting consolidation in fragmented markets

Charterhouse–Animalcare and the Zenex platform strategy show how investors can combine established brands, product development, distribution and international reach. Value creation depends on integration discipline, regulatory compliance, portfolio quality and sustainable commercial growth—not simply the number of acquisitions.

Cross-border expansion remains important

Alivira–BioForLife and the Ceva–Mitsui joint venture illustrate two different approaches: acquiring an established market platform and creating a joint venture with local distribution capabilities. Both strategies can accelerate market entry, but the financial terms and actual post-transaction performance need to be tracked separately.

The feed and food supply chain remains relevant to animal health

SALIC–Olam Agri is not a direct animal-health transaction, but it illustrates the strategic importance of global agricultural assets and supply chains. Its relevance to animal-health analysts is indirect, through feed economics, livestock production and food-system resilience.

Conclusion

From January to September 2026, animal-health M&A ranged from large-scale portfolio restructuring and distribution consolidation to specialised acquisitions in veterinary diagnostics, genetics, biotechnology and companion-animal services. The period also featured veterinary-practice mergers and transactions involving pet nutrition, real estate and agricultural supply chains.

The clearest publicly disclosed financial benchmarks in this compilation include:

• US$3.5bn enterprise value: MWI Animal Health transaction announced by Covetrus and Cencora.

• €2.2bn enterprise value: Proposed sale of dsm-firmenich Animal Nutrition & Health to CVC, including an earn-out of up to €500m.

• US$399.8m purchase price: Chewy’s completed acquisition of Modern Animal.

• £235.2m equity value: Charterhouse’s completed acquisition of Animalcare Group.

• US$316m maximum disclosed consideration: Elanco’s AHV acquisition, comprising US$76m paid at closing plus guaranteed and contingent payments.

• US$160m transaction value: Zoetis’ proposed acquisition of Neogen’s animal-genomics business.

• US$268m maximum property purchase price: Four Corners’ agreement to acquire up to 102 Mission Pet Health properties; this is not an acquisition of the veterinary operating company.

• US$1.88bn stake purchase: SALIC’s acquisition of an additional 44.58% of Olam Agri, an adjacent agribusiness transaction.

Disclaimer – This is a best-efforts’ reprot and this report may not cover an exhaustive list of all the reported transactions in Animal Health in 2026 so far. This report may have missed a few deals – due caution is warranted.